Patent ID: 11969443
Assignee: LENTIGEN TECHNOLOGY, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating a hematological cancer in a human subject in need thereof, the method comprising administering to the human subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of autologous T cells, wherein each cell of the population of autologous T cells comprises a nucleic acid sequence that encodes a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 78, wherein the nucleic acid comprises a surface antigen-regulated inducible promoter comprising the nucleotide sequence of SEQ ID NO: 138 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, operably linked to the CAR encoding sequence, wherein the surface antigen-regulated inducible promoter adjusts its level of transcription dependent upon the level of expression of surface antigen on a target cell, thereby treating the hematological cancer of the human subject.